Alveolar Bone ResorptionNCT05975138
Trans-gingival or Subcrestal Short Implants Posterior Maxilla Bone Changes
An observational study of Alveolar Bone Resorption, run by International Piezosurgery Academy at 1 site in Italy.
Trial summary
two groups of inserted implants: trans-gingival and under-bone level; difference in the marginal bone loss at six months from placement between the two groups of implant positioned in the posterior atrophic maxilla Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Alveolar Bone Resorption
- What is being tested?
- implant insertion
- Type of treatment
- Surgery or procedure
- How many people
- 22 participants
- Where
- 1 siteItaly
- Study dates
- 15 Jun 2021to 15 Jul 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- Adult, Older adult
Study population: people with an edentulous site in the posterior maxilla
Who may be able to join
- 1) indications for an implant-prosthetic rehabilitation of a single edentulism in the upper posterior arch, on the basis of an accurate diagnosis and treatment planning;
- 2) the bone crest must be healed (at least six months after tooth loss);
- 3) residual bone crest width ≥6 mm;
- 4) presence of an available bone height between 4.5 and 8.5 mm on the floor of the maxillary sinus in the area of the planned implant insertion;
- 5) patient age >18 years;
- 6) the patient must not wear any type of removable prosthesis on the treated area;
- 7) the patient must be able to follow the study protocol;
- 8) written informed consent
Who cannot join
- 1) acute myocardial infarction in the last 2 months;
- 2) uncontrolled bleeding disorders;
- 3) uncontrolled diabetes (HBA1c > 7.5);
- 4) head/neck radiotherapy in the last 24 months;
- 5) immunocompromised patients, HIV positive or undergoing chemotherapy in the last 5 years;
- 6) current or past treatment with intravenous bisphosphonates;
Show all 9Show fewer
- 7) psychological or psychiatric problems;
- 8) alcohol or drug abuse;
- 9) The local exclusion criterion is the presence of uncontrolled periodontal disease
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Marginal Bone Level Changes in Trans-gingival or Subcrestal Level Short Implants in the Atrophic Posterior Maxilla.
two groups of inserted implants: trans-gingival and under-bone level; difference in the marginal bone loss at six months from placement between the two groups of implant positioned in the posterior atrophic maxilla
Read the detailed description
The inserted implants will be divided into two groups (group A: trans-gingival implants; group B: under bone level implants): a sample of 17 implants for each group was calculated to be necessary to detect a statistically significant difference in the marginal bone loss at six months from placement between the two groups (primary outcome) (alpha level set at 0.05 and statistical power at 80%) (Primer 6.0, Mc Graw-Hill, USA). The expected differences in marginal bone loss between groups (0.1 ±0.1 mm) were extrapolated from literature studies conducted on the topic10. Each center will treat 15 patients who need to insert implants in the posterior maxillary area, for a total of 45 implants, in order to compensate for any drop-outs.
Training and calibration session. Before the start of the study, a meeting will be held between all clinical centers to explain the surgical protocol, in order to ensure that clinical operators apply a standardized approach. A clinical operator for each center will receive written instructions regarding the evaluation of the experimental parameters in order to obtain repeatability in the collection of clinical parameters and in the compilation of the Case Report Form.
Screening stage.
All patients treated by the Clinical Centers are eligible to enter this study. Prior to enrollment, all patients will be required to sign an informed consent form to document that they understand the purpose of the study (including procedures, follow-up assessments, and potential risks involved). Patients will be allowed to ask questions related to this study and will be informed about alternative treatments.
Surgical procedure.
Presurgical planning will be performed with cone-beam computed tomography examination with or without the use of image reconstruction software.
After local anesthesia using articaine 4% with epinephrine 1:100,000, a minimally invasive full-thickness flap will be raised in order to visualize the anatomy of the ridge. The vertical thickness of the supracrestal soft tissue will be measured and recorded. The preparation of the implant site will be performed with rotary burs and the bone quality will be recorded. An implant (M2 Short, M2 Implants, Padova, Italy), 4 mm in diameter and 5, 6.5 or 7 mm in length, will be placed according to the manufacturer's recommendations (5 and 6.5 crestal placement; 7 subcrestal placement of 1 mm ). The length of the implant will be chosen in order to obtain a bicortical anchorage on the floor of the maxillary sinus.
Immediately after implant placement, an intraoral radiograph will be performed and an operator will record the implant stability values in the mesio-distal, disto-mesial, bucco-lingual and lingual-buccal directions. Dedicated disposable transducers and a measuring device will be used. The calibration of the instrument will be checked before and after each patient visit, using an implant fixed in a block of resin.
The flap will be sutured around the implant (one-stage protocol) with a non-absorbable monofilament, and an intraoral radiography with a centering device will be performed.
Patients will be prescribed antibiotics (amoxicillin/clavulanic acid 1 g 2 tablets/day from one day before surgery to five days after - clarithromycin 500 mg 1 tablet/day in allergic patients), NSAID (ibuprofen 600 mg as needed) and mouthwashes of chlorhexidine 0.2% lasting two minutes, three times a day.
The sutures will be removed 14 days after the surgery.
Postoperative recalls. After four months of healing, after periapical radiography and implant stability control , the final impression will be taken for the construction of the prosthetic product. The prosthetic rehabilitation will consist of single screw-retained ceramic crowns. Periapical radiographs will be performed upon delivery of the prosthetic product, after six months, one year, three and five years of prosthetic loading to evaluate the stability of the marginal bone.
Data analysis and retention. For each clinical center, a trained clinical operator and a clinical assistant will take care of data collection (filling in the case report form, performing periapical radiographs (on digital support) and measuring implant stability quotient values. Case report forms, radiographs and implant stability quotient measurements will be sent to the Coordination Centre, where trained operators will perform all measurements. The data will be transferred into a single electronic dataset for subsequent analysis. The examiners will not have been involved in the surgical and prosthetic phases and will proceed with the observation of the radiographs in a blind manner.
- Conditions
- Alveolar Bone Resorption
- Being tested
- implant insertion
- Keywords
- bone atrophy, dental implant, bone remodeling
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
implant insertionProcedure or surgery
Also called dental implant positioning
a minimally invasive full-thickness flap will be raised in order to visualize the anatomy of the ridge. The vertical thickness of the supracrestal soft tissue will be measured and recorded. The preparation of the implant site will be performed with rotary burs and the bone quality will be recorded. An implant will be placed according to the manufacturer's recommendations. The length of the implant will be chosen in order to obtain a bicortical anchorage on the floor of the maxillary sinus
| Study group | Role | What they receive |
|---|---|---|
| trans-gingival short implants | trans-gingival implant insertion in the posterior atrophic maxilla Receives: Procedure: implant insertion | |
| subcrestal short implants | subcrestal implant insertion in the posterior atrophic maxilla Receives: Procedure: implant insertion |
What is being measured
The primary outcome is the main question the study is designed to answer.
marginal bone loss
millimeter of peri-implant bone resorption
Measured: six months
Secondary outcomes (1)
marginal bone loss
millimeter of peri-implant bone resorption
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2023
- Study start15 Jun 2021
- Primary completion15 Jun 2023
- Study completion15 Jul 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Alveolar Bone ResorptionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- International Piezosurgery Academy
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- claudio stacchi, dr, Study chair, International Piezoelectric surgery Academy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05975138
- Sponsor's protocol ID
- M2TRANS-SUB
- Status last verified
- Jul 2023
- First submitted
- 26 Jul 2023
- Last updated
- 3 Aug 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: only after data elaboration
Publications
Fan T, Li Y, Deng WW, Wu T, Zhang W. Short Implants (5 to 8 mm) Versus Longer Implants (>8 mm) with Sinus Lifting in Atrophic Posterior Maxilla: A Meta-Analysis of RCTs. Clin Implant Dent Relat Res. 2017 Feb;19(1):207-215. doi: 10.1111/cid.12432. Epub 2016 Jun 13.
PubMed 27295262Han HC, Lim HC, Hong JY, Ahn SJ, Han JY, Shin SI, Chung JH, Herr Y, Shin SY. Primary implant stability in a bone model simulating clinical situations for the posterior maxilla: an in vitro study. J Periodontal Implant Sci. 2016 Aug;46(4):254-65. doi: 10.5051/jpis.2016.46.4.254. Epub 2016 Aug 30.
PubMed 27588215Mezzomo LA, Miller R, Triches D, Alonso F, Shinkai RS. Meta-analysis of single crowns supported by short (<10 mm) implants in the posterior region. J Clin Periodontol. 2014 Feb;41(2):191-213. doi: 10.1111/jcpe.12180. Epub 2013 Nov 25.
PubMed 24266703
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Marginal Bone Level Changes in Trans-gingival or Subcrestal Level Short Implants in the Atrophic Posterior Maxilla.
- ClinicalTrials.gov ID
- NCT05975138
- Acronym / sponsor ID
- M2TRANS-SUB
- Conditions
- Alveolar Bone Resorption
- Keywords
- bone atrophy, dental implant, bone remodeling
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- International Piezosurgery AcademyUniversity, hospital or other
- Study start
- 15 Jun 2021 (actual)
- Primary completion
- 15 Jun 2023 (actual)
- Study completion
- 15 Jul 2023 (actual)
- First posted
- 3 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
two groups of inserted implants: trans-gingival and under-bone level; difference in the marginal bone loss at six months from placement between the two groups of implant positioned in the posterior atrophic maxilla
Detailed description
The inserted implants will be divided into two groups (group A: trans-gingival implants; group B: under bone level implants): a sample of 17 implants for each group was calculated to be necessary to detect a statistically significant difference in the marginal bone loss at six months from placement between the two groups (primary outcome) (alpha level set at 0.05 and statistical power at 80%) (Primer 6.0, Mc Graw-Hill, USA). The expected differences in marginal bone loss between groups (0.1 ±0.1 mm) were extrapolated from literature studies conducted on the topic10. Each center will treat 15 patients who need to insert implants in the posterior maxillary area, for a total of 45 implants, in order to compensate for any drop-outs.
Training and calibration session. Before the start of the study, a meeting will be held between all clinical centers to explain the surgical protocol, in order to ensure that clinical operators apply a standardized approach. A clinical operator for each center will receive written instructions regarding the evaluation of the experimental parameters in order to obtain repeatability in the collection of clinical parameters and in the compilation of the Case Report Form.
Screening stage.
All patients treated by the Clinical Centers are eligible to enter this study. Prior to enrollment, all patients will be required to sign an informed consent form to document that they understand the purpose of the study (including procedures, follow-up assessments, and potential risks involved). Patients will be allowed to ask questions related to this study and will be informed about alternative treatments.
Surgical procedure.
Presurgical planning will be performed with cone-beam computed tomography examination with or without the use of image reconstruction software.
After local anesthesia using articaine 4% with epinephrine 1:100,000, a minimally invasive full-thickness flap will be raised in order to visualize the anatomy of the ridge. The vertical thickness of the supracrestal soft tissue will be measured and recorded. The preparation of the implant site will be performed with rotary burs and the bone quality will be recorded. An implant (M2 Short, M2 Implants, Padova, Italy), 4 mm in diameter and 5, 6.5 or 7 mm in length, will be placed according to the manufacturer's recommendations (5 and 6.5 crestal placement; 7 subcrestal placement of 1 mm ). The length of the implant will be chosen in order to obtain a bicortical anchorage on the floor of the maxillary sinus.
Immediately after implant placement, an intraoral radiograph will be performed and an operator will record the implant stability values in the mesio-distal, disto-mesial, bucco-lingual and lingual-buccal directions. Dedicated disposable transducers and a measuring device will be used. The calibration of the instrument will be checked before and after each patient visit, using an implant fixed in a block of resin.
The flap will be sutured around the implant (one-stage protocol) with a non-absorbable monofilament, and an intraoral radiography with a centering device will be performed.
Patients will be prescribed antibiotics (amoxicillin/clavulanic acid 1 g 2 tablets/day from one day before surgery to five days after - clarithromycin 500 mg 1 tablet/day in allergic patients), NSAID (ibuprofen 600 mg as needed) and mouthwashes of chlorhexidine 0.2% lasting two minutes, three times a day.
The sutures will be removed 14 days after the surgery.
Postoperative recalls. After four months of healing, after periapical radiography and implant stability control , the final impression will be taken for the construction of the prosthetic product. The prosthetic rehabilitation will consist of single screw-retained ceramic crowns. Periapical radiographs will be performed upon delivery of the prosthetic product, after six months, one year, three and five years of prosthetic loading to evaluate the stability of the marginal bone.
Data analysis and retention. For each clinical center, a trained clinical operator and a clinical assistant will take care of data collection (filling in the case report form, performing periapical radiographs (on digital support) and measuring implant stability quotient values. Case report forms, radiographs and implant stability quotient measurements will be sent to the Coordination Centre, where trained operators will perform all measurements. The data will be transferred into a single electronic dataset for subsequent analysis. The examiners will not have been involved in the surgical and prosthetic phases and will proceed with the observation of the radiographs in a blind manner.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| trans-gingival short implants | – | Procedure: implant insertiontrans-gingival implant insertion in the posterior atrophic maxilla |
| subcrestal short implants | – | Procedure: implant insertionsubcrestal implant insertion in the posterior atrophic maxilla |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- people with an edentulous site in the posterior maxilla
Key inclusion criteria (8 listed)
- 1) indications for an implant-prosthetic rehabilitation of a single edentulism in the upper posterior arch, on the basis of an accurate diagnosis and treatment planning;
- 2) the bone crest must be healed (at least six months after tooth loss);
- 3) residual bone crest width ≥6 mm;
- 4) presence of an available bone height between 4.5 and 8.5 mm on the floor of the maxillary sinus in the area of the planned implant insertion;
- 5) patient age >18 years;
Key exclusion criteria (9 listed)
- 1) acute myocardial infarction in the last 2 months;
- 2) uncontrolled bleeding disorders;
- 3) uncontrolled diabetes (HBA1c > 7.5);
- 4) head/neck radiotherapy in the last 24 months;
- 5) immunocompromised patients, HIV positive or undergoing chemotherapy in the last 5 years;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| implant insertionAlso: dental implant positioninga minimally invasive full-thickness flap will be raised in order to visualize the anatomy of the ridge. The vertical thickness of the supracrestal soft tissue will be measured and recorded. The preparation of the implant site will be performed with rotary burs and the bone quality will be recorded. An implant will be placed according to the manufacturer's recommendations. The length of the implant will be chosen in order to obtain a bicortical anchorage on the floor of the maxillary sinus | Procedure or surgery | subcrestal short implants, trans-gingival short implants |
Primary outcome
marginal bone loss
Time frame: six months
millimeter of peri-implant bone resorption
1 secondary outcome
marginal bone loss
Time frame: one year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2023.
- Background: PubMed 27295262Fan T, Li Y, Deng WW, Wu T, Zhang W. Short Implants (5 to 8 mm) Versus Longer Implants (>8 mm) with Sinus Lifting in Atrophic Posterior Maxilla: A Meta-Analysis of RCTs. Clin Implant Dent Relat Res. 2017 Feb;19(1):207-215. doi: 10.1111/cid.12432. Epub 2016 Jun 13.
- Background: PubMed 27588215Han HC, Lim HC, Hong JY, Ahn SJ, Han JY, Shin SI, Chung JH, Herr Y, Shin SY. Primary implant stability in a bone model simulating clinical situations for the posterior maxilla: an in vitro study. J Periodontal Implant Sci. 2016 Aug;46(4):254-65. doi: 10.5051/jpis.2016.46.4.254. Epub 2016 Aug 30.
- Background: PubMed 24266703Mezzomo LA, Miller R, Triches D, Alonso F, Shinkai RS. Meta-analysis of single crowns supported by short (<10 mm) implants in the posterior region. J Clin Periodontol. 2014 Feb;41(2):191-213. doi: 10.1111/jcpe.12180. Epub 2013 Nov 25.
- Individual participant dataSharing planned: No. only after data elaboration
Related trials for Alveolar Bone Resorption
Recruiting
The Application of a Biphasic Calcium Sulfate Graft Material in Sinus Floor Elevation
Alveolar Bone Loss, Edentulism Nos
Enrolling by invitation
Investigation of the Effect of Horizontal Platelet Rich Fibrin Placed in Tooth Extraction Sockets on Bone Formation
Tooth Loss, Dental Implant Failed
Recruiting
Effect of Collagen Membrane on Ridge Preservation
Dehiscence, Tooth Extraction
Not yet recruitingPhase 1/2
Alveolar Ridge Preservation (ARP) Study Using Alloplastic Biomaterial and a Resorbable Synthetic Membrane. A Digital Workflow (CBCT/Scanner) Evaluates Hard and Soft Tissue Volumetric Changes at 4 Months, Validating Support for the Gingival Phenotype and Buccal Bone Plate.
Alveolar Ridge Augmentation, Bone Substitutes
Recruiting
Melatonin Effect on Immediate Dental Implants in the Posterior Mandible
Dental Implant, Immediate Dental Implant Placement
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
claudio stacchi, dr study chair
International Piezoelectric surgery Academy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alveolar Bone Resorption, run by International Piezosurgery Academy at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
marginal bone loss (time frame: six months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05975138, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2023.